Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06079190 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

A Phase 2 study of Alzheimers Disease, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
367
Enrollment target
20
Study locations

NCT06079190 is a Phase 2 study of Alzheimers Disease that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 367 participants, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06079190, a Phase 2 study of Alzheimers Disease, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
367 participants
Enrollment target
20
Study locations

Study Summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Conditions Studied

Alzheimers Disease

Interventions

  • OTHER Placebo
  • DRUG GSK4527226

Study Locations (20)

Florida

  • GSK Investigational Site - Lake Mary
  • GSK Investigational Site - Lake Worth
  • GSK Investigational Site - Maitland
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Orlando
  • GSK Investigational Site - Orlando
  • GSK Investigational Site - Stuart
  • GSK Investigational Site - The Villages
  • GSK Investigational Site - The Villages

California

  • GSK Investigational Site - San Diego

Georgia

  • GSK Investigational Site - Decatur

Illinois

  • GSK Investigational Site - Elk Grove Village

Missouri

  • GSK Investigational Site - Chesterfield

New Jersey

  • GSK Investigational Site - Toms River

New York

  • GSK Investigational Site - Staten Island

North Carolina

  • GSK Investigational Site - Matthews

Trial Details

FieldValue
Enrollment Target 367 participants
Start Date 2023-10-20
Est. Completion 2026-11-23
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06079190

The ClinicalTrials.gov registry entry for NCT06079190 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (91% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06079190 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06079190 about?

NCT06079190 is a clinical study titled "Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease". The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

What is the current status of trial NCT06079190?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 367 participants. The study started on 2023-10-20. Estimated completion is 2026-11-23.

What conditions does trial NCT06079190 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT06079190?

The interventions under investigation include: Placebo (OTHER), GSK4527226 (DRUG).

Who is sponsoring clinical trial NCT06079190?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06079190 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.